Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-111077 in advanced solid tumor
NCT02250170Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Oct 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OPB-111077 in solid tumor, sponsored by Otsuka Holdings. Primary endpoints: Adverse Events at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Oct 2014; status: completed.
02
Drugs
OPB-111077
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02250170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250170.